Welcome to our dedicated page for Tyra Biosciences SEC filings (Ticker: TYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tyra Biosciences’ 10-K can stretch beyond 200 pages of R&D detail, clinical-trial tables, and complex royalty clauses—daunting for even seasoned biotech investors. If you came here looking for Tyra Biosciences insider trading Form 4 transactions or need the Tyra Biosciences quarterly earnings report 10-Q filing, you already know the challenge: crucial data is scattered across multiple forms, each released at different times.
Stock Titan solves this problem. Our AI reads every submission the moment it hits EDGAR and delivers Tyra Biosciences SEC filings explained simply. Get AI-powered summaries that pull out runway length, trial milestones, and collaboration terms. Real-time alerts surface Tyra Biosciences Form 4 insider transactions real-time, while side-by-side views make Tyra Biosciences earnings report filing analysis painless. It’s all part of understanding Tyra Biosciences SEC documents with AI—no pharmacology PhD required.
The platform covers every disclosure type investors track: the Tyra Biosciences annual report 10-K simplified highlights clinical risks; 10-Qs map quarter-over-quarter cash burn; 8-Ks flag trial read-outs, giving you Tyra Biosciences 8-K material events explained minutes after filing. Looking for governance details? Access the full Tyra Biosciences proxy statement executive compensation. Want to monitor management confidence? Drill into Tyra Biosciences executive stock transactions Form 4. From S-3 shelf registrations that hint at future capital raises to Section 16 filings that reveal insider sentiment, Stock Titan provides the complete picture—updated continuously and distilled into clear, actionable insights.
Tyra Biosciences (TYRA) reported a wider quarterly net loss as it advanced multiple clinical programs. For the three months ended September 30, 2025, the company posted a net loss of $29.9 million versus $24.0 million a year ago. Operating expenses rose to $32.9 million, driven by R&D of $25.5 million and G&A of $7.5 million, while interest and other income contributed $3.1 million.
Liquidity remains strong with cash, cash equivalents and marketable securities of $274.9 million as of September 30, 2025. Net cash used in operations was $71.5 million for the first nine months of 2025. Management states this cash position is expected to fund operations through at least 2027.
Development highlights include progress across FGFR programs: dabogratinib Phase 2 studies in pediatric achondroplasia (BEACH301) and NMIBC (SURF302) are underway, UTUC (SURF303) received FDA clearance to initiate Phase 2, and TYRA-430 began dosing in a global Phase 1. Shares outstanding were 53,318,198 as of September 30, 2025; 53,372,098 were outstanding as of October 31, 2025.
Tyra Biosciences, Inc. filed an 8-K announcing it issued a press release covering financial results for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.
Consistent with General Instruction B.2, the information in this report, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. The filing lists the company’s common stock under the symbol TYRA on the Nasdaq Global Select Market.
Tyra Biosciences insider purchase under ESPP: The company's Chief Financial Officer, Alan Fuhrman, acquired 701 shares of Tyra Biosciences common stock on 09/15/2025 at a purchase price of $9.129 per share under the issuer's 2021 Employee Stock Purchase Plan. After the transaction, Mr. Fuhrman beneficially owned 14,788 shares. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Tyra Biosciences (TYRA) reported items from its Quarterly Report that describe capital structure, recent equity transactions, stock plan availability, cost drivers and development risks. The company had 53,233,494 shares issued and outstanding at June 30, 2025, compared with 50,754,262 issued and 50,749,945 outstanding at December 31, 2024. A 2022 Sales Agreement was terminated in May 2025 and no shares were sold under it; no shares had been sold under a 2025 Sales Agreement as of June 30, 2025. RA Capital exchanged 1,000,000 shares for pre-funded warrants exercisable at $0.001 per share; the Exchange closed October 22, 2024, and the warrants are classified in stockholders' equity. As of June 30, 2025, 5,189,786 shares were available for future grant under the 2021 Plan and 1,972,762 shares remained available for purchase under the ESPP, which offers a purchase price at 85% of the lower of two dates. The company disclosed increases in costs: $4.1 million and $9.6 million driven by clinical start-up and CMC activities, and increases of $2.4 million and $4.5 million in compensation and personnel expenses (including $1.0 million and $2.2 million higher stock-based compensation), partially offset by $0.2 million lower facilities costs. The filing lists numerous development, regulatory, operational and geopolitical risks that could affect timelines, costs and commercialization prospects.
Janus Henderson Group plc reported beneficial ownership of 2,856,290 shares of Tyra Biosciences common stock, equal to 5.4% of the class, in a Schedule 13G/A filing. The statement shows 0 shares of sole voting or dispositive power and 2,856,290 shares of shared voting and shared dispositive power, indicating the reported interest is held collectively by related entities. The filing identifies the reporting person type as IA, HC and lists indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) as registered investment advisers furnishing advice to Managed Portfolios. A power of attorney authorizes named employees to prepare and file U.S. reporting forms on the group's behalf.
FAQ
What is the current stock price of Tyra Biosciences (TYRA)?
What is the market cap of Tyra Biosciences (TYRA)?
